Bioactive sphingolipids in docetaxel-induced apoptosis in human prostate cancer cells

Biomedicine and Pharmacotherapy

Volumn 66, Issue 2, 2012, Pages 103-110

  Bassoy, Esen Yonca ^a   Baran, Yusuf ^a  

^a IZMIR INSTITUTE OF TECHNOLOGY   (Turkey)

Author keywords

Bioactive sphingolipids; Ceramides; Docetaxel; Glucosyle ceramide synthase; Prostate cancer; Sphingosine kinase

Indexed keywords

CERAMIDE 1 PHOSPHATE; CERAMIDE GLUCOSYLTRANSFERASE; DOCETAXEL; SPHINGOSINE 1 PHOSPHATE;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER CELL; DOWN REGULATION; DRUG SENSITIVITY; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CERAMIDES; DOWN-REGULATION; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOSYLCERAMIDES; GLUCOSYLTRANSFERASES; HUMANS; LYSOPHOSPHOLIPIDS; MALE; OXIDOREDUCTASES; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SPHINGOSINE; TAXOIDS; UP-REGULATION;

EID: 84858287935     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2011.10.003     Document Type: Article

References (29)

1. Visakorpi T. The molecular genetics of prostate cancer. Urology 1998, 62:3-10.
2. Schulz W.A., Burchardt M., Cronauer M.V. Molecular biology of prostate cancer. Mol Hum Reprod 2003, 9(8):437-448.
3. Basler M., Groettrup M. Advances in prostate cancer immunotherapies. Drugs Aging 2007, 24(3):197-221.
4. Kish J.A., Bukkapatnam R., Palazzo F. The treatment challenge of hormone-refractory prostate cancer. Cancer Control 2001, 8(6):487-495.
5. Kraus L.A., Samuel S.K., Schmid S.M., Dykes D.J., Waud W.R., Bissery M.C. The mechanism of action of docetaxel (Taxotere) in xenograft models is not limited to bcl-2 phosphorylation. Invest New Drugs 2003, 21(3):259-268.
6. Ting H.J., Hsu J., Bao B.Y., Lee Y.F. Docetaxel-induced growth inhibition and apoptosis in androgen-independent prostate cancer cells are enhanced by 1alpha, 25-dihydroxyvitamin D3. Cancer Lett 2007, 247(1):122-129.
7. Fillet M., Bentires-Alj M., Deregowski V., Greimers R., Gielen J., Piette J., et al. Mechanisms involved in exogenous C2- and C6-ceramide-induced cancer cell toxicity. Biochem Pharmacol 2003, 65(10):1633-1642.
8. Macchia M., Bertini S., Fogli S., Giovannetti E., Minutolo F., Rapposelli S., et al. Ceramide analogues in apoptosis: a new strategy for anticancer drug development. Farmaco 2003, 58(3):205-211.
9. Devalapally H., Duan Z., Seiden M.V., Amiji M.M. Paclitaxel and ceramide coadministration in biodegradable polymeric nanoparticulate delivery system to overcome drug resistance in ovarian cancer. Int J Cancer 2007, 121(8):1830-1838.
10. Senchenkov A., Litvak D.A., Cabot M.C. Targeting ceramide metabolism a strategy for overcoming drug resistance. J Natl Cancer I 2001, 93(5):347-357.
11. Kiguchi K., Iwamori Y., Suzuki N., Kobayashi Y., Ishizuka B., Ishiwata I., et al. Characteristic expression of globotriaosyl ceramide in human ovarian carcinoma-derived cells with anticancer drug resistance. Cancer Sci 2006, 7(12):1321-1326.
12. Merrill A.H., Wang M.D., Park M., Sullards M.C. (Glyco)sphingolipidology: an amazing challenge and opportunity for systems biology. Trends Biochem Sci 2007, 32(10):457-468.
13. Gouazé-Andersson V., Yu J.Y., Kreitenberg A.J., Bielawska A., Giuliano A.E., Cabot M.C. Ceramide and glucosylceramide upregulate expression of the multidrug resistance gene MDR1 in cancer cells. Biochim Biophys Acta 2007, 1771(12):1407-1417.
14. Hannun Y.A., Obeid L.M. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol 2008, 9(2):139-150.
15. Huwiler A., Pfeilschifter J. New players on the center stage: sphingosine 1-phosphate and its receptors as drug targets. Biochem Pharmacol 2008, 75(10):1893-1900.
16. Melendez A.J. Sphingosine kinase signalling in immune cells: potential as novel therapeutic targets. Biochim Biophys Acta 2008, 1784(1):66-75.
17. Baran Y., Salas A., Senkal C.E., Gunduz U., Bielawski J., Obeid L.M., et al. Alterations of ceramide/sphingosine 1-phosphate rheostat involved in the regulation of resistance to imatinib-induced apoptosis in K562 human chronic myeloid leukemia cells. J Biol Chem 2007, 282(15):10922-10934.
18. Leroux M.E., Auzenne E., Evans R., Hail N., Spohn W., Ghosh S.C., et al. Sphingolipids and the sphingosine kinase inhibitor, SKI II, induce BCL-2-independent apoptosis in human prostatic adenocarcinoma cells. Prostate 2007, 67(15):1699-1717.
19. Van Helden P.D., Wiid I.J., Hoal-van Helden E.G., Bey E., Cohen R. Detection by DNA fingerprinting of somatic changes during the establishment of a new prostate cell line. Br J Cancer 1994, 70(2):195-198.
20. Kaighn M.E., Narayan K.S., Ohnuki Y., Lechner J.F., Jones L.W. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 1979, 17(1):16-23.
21. Piskin O., Ozcan M.A., Ozsan G.H., Ates H., Demirkan F., Alacacioglu I., et al. Synergistic effect of imatinib mesylate and fludarabine combination on Philadelphia chromosome-positive chronic myeloid leukemia cell lines. Turk J Hematol 2007, 24:23-27.
22. Zhao L., Au J.L., Wientjes M.G. Comparison of methods for evaluating drug-drug interaction. Front Biosci (Elite Ed) 2010, 2:241-249.
23. Desai A., Vyas T., Amiji M. Cytotoxicity and apoptosis enhancement in brain tumor cells upon coadministration of paclitaxel and ceramide in nanoemulsion formulations. J Pharmacol Sci 2008, 97(7):2745-2756.
24. Ji C., Yang B., Yang Y.L., He S.H., Miao D.S., He L., et al. Exogenous cell-permeable C6-ceramide sensitizes multiple cancer cell lines to Doxorubicin-induced apoptosis by promoting AMPK activation and mTORC1 inhibition. Oncogene 2010, 29(50):6557-6568.
25. Ahn E.H., Schroeder J.J. Induction of apoptosis by sphingosine, sphinganine, and C(2)-ceramide in human colon cancer cells, but not by C(2)-dihydroceramide. Anticancer Res 2010, 30(7):2881-2884.
26. Chen J.Y., Hwang C.C., Chen W.Y., Lee J.C., Fu T.F., Fang K., et al. Additive effects of C(2)-ceramide on paclitaxel-induced premature senescence of human lung cancer cells. Life Sci 2010, 87(11-12):350-357.
27. Giovannetti E., Leon L.G., Bertini S., Macchia M., Minutolo F., Funel N., et al. Study of apoptosis induction and deoxycytidine kinase/cytidine deaminase modulation in the synergistic interaction of a novel ceramide analog and gemcitabine in pancreatic cancer cells. Nucleosides Nucleotides Nucleic Acids 2010, 29(4-6):419-426.
28. Dijkhuis A.J., Klappe K., Jacobs S., Kroesen B.J., Kamps W., Sietsma H., et al. PDMP sensitizes neuroblastoma to paclitaxel by inducing aberrant cell cycle progression leading to hyperploidy. Mol Cancer Ther 2010, 5(3):593-601.
29. Liu Y.Y., Patwardhan G.A., Bhinge K., Gupta V., Gu X., Jazwinski S.M. Suppression of glucosylceramide synthase restores p53-dependent apoptosis in mutant p53 cancer cells. Cancer Res 2011, 71(6):2276-2285.